

Association of Uric Acid to Creatinine Ratio with Metabolic Dysfunction-Associated Fatty Liver in Non-Obese Individuals Without Type 2 Diabetes Mellitus

Jing Liu¹, Che Wang², Yutong Wang², Shukun Yao³

¹China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China; ²School of Qi Huang, Beijing University of Chinese Medicine, Beijing, People's Republic of China; ³Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, People's Republic of China

Correspondence: Shukun Yao, Email shukun Yao@126.com

Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease, which is usually associated with type 2 diabetes mellitus (T₂DM) and obesity. However, the incidence of MAFLD in non-obese individuals without T₂DM is increasing, and the pathogenesis is unclear. Serum uric acid to creatinine ratio (sUA/Cr) can reflect overall metabolic status. This study aims to observe the association between sUA/Cr and MAFLD in non-obese individuals without T₂DM.

Methods: A total of 21,996 individuals were included in this study. The subjects were divided into four subgroups: non-obese patients without T₂DM, obese patients without T₂DM, non-obese patients with T₂DM, and obese patients with T₂DM. Logistic regression analyzed the correlation between sUA/Cr and MAFLD subgroups. Receiver operating characteristics analyzed the predictive value of sUA/Cr for MAFLD subgroups. The stratified analyses by sex and age were performed.

Results: Non-obese MAFLD individuals without T₂DM had higher sUA/Cr levels than their counterparts. sUA/Cr was significantly correlated positively with MAFLD in non-obese patients. Similar results were observed in both males and females and in populations at all age stages (all $p < 0.01$). sUA/Cr was capable of discriminating MAFLD in non-obese individuals without T₂DM (AUC: 0.667), especially for patients over 60 years old (AUC: 0.704).

Conclusion: The sUA/Cr ratio was correlated with MAFLD in non-obese patients without T₂DM. The predictive value of sUA/Cr for MAFLD was observed. Hence, the sUA/Cr ratio might be given more concern for the risk of MAFLD in non-obese individuals without T₂DM.

Keywords: uric acid, creatinine, metabolic dysfunction-associated fatty liver disease, non-obesity, type 2 diabetes mellitus

Introduction

Metabolic dysfunction-associated fatty liver disease (MAFLD) is defined as a condition of excessive fat deposition in the liver, accompanied by obesity, metabolic disorders, or type 2 diabetes (T₂DM).¹ MAFLD is recognized as a common chronic liver disease, the prevalence of which is about 39% all over the world.² The latest consensus suggests that MAFLD should be divided into three subgroups according to different diagnostic modalities, including obesity, non-obesity, and T₂DM subgroups.³ The risk of MAFLD is often highlighted in obese and diabetic patients, but not in non-obese individuals due to deceptive body mass index (BMI) and euglycemia.⁴ However, the prevalence of non-obese MAFLD ranges from 5% to 45%.⁵ Further research indicated that non-obese MAFLD might be a distinct pathophysiological entity, with half progressing into NASH, which has a higher mortality rate and accelerated disease progression despite a more benign metabolic profile.⁶⁻⁸ Hence, it is important to identify the risk of MAFLD in non-obese normoglycemic patients at an early stage.

Uric acid (UA) is a product of purine metabolism taking part in lipid and glucose metabolism.^{9,10} Serum uric acid to creatinine ratio (sUA/Cr) can reflect the level of sUA while excluding the influence of kidney diseases. Research conducted by She D et al suggested that sUA/Cr was significantly associated with metabolic syndrome.¹¹ UA was also found to be associated with sarcopenia, which is presented in many cases of MAFLD.^{12,13} Previous evidence suggested serum uric acid (sUA) plays a critical role in the incidence and development of MAFLD, and the high level of sUA is correlated with BMI.¹⁴ However, the association of sUA with non-obese MAFLD in normo-glycemic individuals is unclear. Considering that the sUA/Cr ratio represents a comprehensive metabolic situation excluding the influence of renal function, this study explored the association of sUA/Cr with non-obese MAFLD in individuals without T₂DM. The stratified analyses by age and sex were performed.

Materials and Methods

Study Design and Participants

The participants consisted of 24,714 Chinese adults from the China–Japan Friendship Hospital from January 2019 to June 2022. The study was approved by the Ethics Committee of the China–Japan Friendship Hospital Clinical Research Ethics Committee in compliance with the Declaration of Helsinki. Informed consent was waived because of the retrospective nature of our study. The data are anonymous.

Inclusion Criteria

1. Individuals who were ≥ 18 years old.

2. Participants were diagnosed with MAFLD as follows, which meet conditions (1) and (2) simultaneously.³

(1) Diagnosis of hepatic steatosis by ultrasound.¹⁰ The inclusion of at least two of the three following conditions was required: ① hypoechogenicity in the far field of the liver; ② hyperechogenicity in the near field of the liver or bright liver, as well as signs of it being stronger than the kidney cortex; and ③ a blurry intrahepatic tubular structure.

(2) Patients who complied with one of the following three conditions were included: ① Obesity: Body mass index (BMI) ≥ 23 kg/m². ② Non-obesity: BMI < 23 kg/m² combining ≥ 2 abnormal metabolic indexes including 1) Waist circumference (WC) ≥ 90 cm in males or 80 cm in females; 2) Blood pressure (BP) $\geq 130/85$ mmHg or taking antihypertensive agents; 3) Plasma triglycerides (TG) ≥ 1.70 mmol/L or taking lipid-lowering agents; 4) Plasma high-density lipoprotein cholesterol (HDL-C) $< 1.0/1.3$ mmol/L for males and females or specific drug treatment; 5) Prediabetes (fasting glucose levels (FPG) 5.6–6.9 mmol/L or 2h postprandial plasma glucose (2h-PPG) 7.8–11.0 mmol/L or HbA1c 5.7%–6.4%); 6) insulin resistance (IR) score ≥ 2.5 ; 7) Plasma high-sensitivity C-reactive protein (hs-CRP) > 2 mg/L. ③ Type 2 diabetes mellitus (T₂DM): The diagnostic criteria were based on international standards.¹⁵

Exclusion Criteria

1. Cushing's syndrome, viral liver disease, and medication history (eg glucocorticoids), which lead to special conditions of liver steatosis. 2. Suffering from serious cardiac-cerebral vascular disease, kidney failure, and malignant tumors. 3. Pregnancy and lactation. 6. Medication history of SGLT-2 inhibitors, GLP-1 receptors agonists, and antihyperuricemic agents.

According to inclusion and exclusion criteria, 21,996 participants were included in the final retrospective cross-sectional analysis (Figure 1).

Data Collection

The subjects were examined in the morning after overnight fasting. The examination included demographic data (age, gender, physical activity, and medication history) using a self-reported questionnaire, and anthropometry (weight, height, WC, and BP). Measurements were replicated three times, and the means were recorded. The abdominal ultrasound examination was performed on the participants by two experienced sonographers. Elbow venous blood was taken to determine the levels of fasting lipids (TG, total cholesterol (TC), HDL-C, and low-density lipoprotein cholesterol (LDL-C)), liver enzymes (alanine transaminase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT)),




Figure 1 Flow chart of the study subjects.

Abbreviations: MAFLD, metabolic dysfunction-associated fatty liver disease; BMI, body mass index; T₂DM, type 2 diabetes mellitus.

FPG, UA, and Cr. Dyslipidemia was defined as TC \geq 5.2 mmol/L or TG \geq 1.7 mmol/L or LDL-C \geq 3.4 mmol/L or HDL-C $<$ 1.0 mmol/L for men and $<$ 1.3 mmol/L for women.¹⁶

Abnormal liver function was defined as AST \geq 42 IU/L or ALT \geq 40 IU/L or GGT \geq 52 IU/L.

Statistical Analysis

The data analysis was processed using SPSS 26.0 statistical software. Continuous variables were expressed as mean \pm standard deviation ($\bar{x} \pm S$) and Student's *t*-test was performed to compare subgroups. Categorical variables were presented as a percentage (%) and analyzed by the chi-square test. To evaluate the association of sUA/Cr with MAFLD, logistic regression was used, and the results were expressed by odds ratios (ORs) with 95% confidence intervals (CI). To assess the predictive value of sUA/Cr, we examined the receiver operating characteristic (ROC) and

calculated the areas under the curves (AUCs) using MedCalc 20.022 statistical software. The optimal cutoff points and the Youden index with sensitivity and specificity were shown. $P < 0.01$ was considered statistically significant.

Results

Clinical Characteristics of the Study Population

In total, 21,996 subjects were analyzed in this study. There were 8855 non-obese individuals without T₂DM who did not have MAFLD and 369 non-obese individuals without T₂DM who had MAFLD (Table 1). MAFLD patients (n=7262) had higher UA, Cr, SUA/Cr, BMI, FPG, percentages of abnormal liver function, dyslipidemia, and hypertension than those in non-MAFLD participants (n=14,734) (all $P < 0.01$) (Table 1). The sUA/Cr ratio in MAFLD patients was higher than non-MAFLD individuals in males (5.44 ± 1.26 vs 4.88 ± 1.08) and females (5.84 ± 1.43 vs 4.84 ± 1.12), and at all age stages (18–39 years old: 5.73 ± 1.29 vs 4.90 ± 1.10 ; 40–59 years old: 5.41 ± 1.29 vs 4.77 ± 1.09 ; ≥ 60 years old: 5.43 ± 1.41 vs 4.88 ± 1.19) (all $P < 0.01$) (Figure 2).

Table 1 Baseline and Clinical Characteristics of Participants with and without Metabolic Dysfunction-Associated Fatty Liver Disease (n=21,996)

	MAFLD (n =7262)	Non-MAFLD (n =14,734)	p
Male [n (%)]	5465 (75.3%)	6121 (41.5%)	0.000
Female [n (%)]	1797 (24.7%)	8613 (58.5%)	
Obesity without T ₂ DM [n (%)]	5903 (81.3%)	5562 (37.7%)	0.000
Non-obesity without T ₂ DM [n (%)]	369 (5.1%)	8855 (60.1%)	0.000
Obesity with T ₂ DM [n (%)]	923 (12.7%)	214 (1.5%)	0.000
Non-obesity with T ₂ DM [n (%)]	67 (0.9%)	103 (0.7%)	0.075
Age (years)	44.16±11.66	38.72±11.02	0.000
BMI (kg/m ²)	27.13±3.31	22.39±2.89	0.000
UA (μ mol/L)	380.79±88.34	306.84±81.58	0.000
Cr (μ mol/L)	70.20±17.48	64.03±14.31	0.000
sUA/Cr	5.54±1.31	4.86±1.10	0.000
FPG (mmol/L)	5.89±1.54	5.19±0.67	0.000
TG (mmol/L)	2.10±1.57	1.09±0.69	0.000
TC (mmol/L)	5.36±0.99	5.10±0.92	0.000
HDL-C (mmol/L)	1.22±0.34	1.46±0.34	0.000
LDL-C (mmol/L)	3.04±0.74	2.72±0.70	0.000
Dyslipidemia [n (%)]	5900 (81.2%)	7364 (50.0%)	0.000
ALT (mmol/L)	37.77±28.21	20.01±17.46	0.000
AST (mmol/L)	25.13±11.82	20.59±8.25	0.000
GGT (IU/L)	38.83±34.92	20.74±20.39	0.000
Abnormal liver function [n (%)]	2658 (36.6%)	1127 (7.6%)	0.000
Tbil (μ mol/L)	12.93±5.20	13.15±5.49	0.004
SBP (mm Hg)	129.60±16.39	117.13±15.33	0.000
DBP (mm Hg)	77.99±11.45	69.64±10.34	0.000
Hypertension [n (%)]	3626 (49.9%)	3091 (21.0%)	0.000
WC (cm)	96.14±9.10	82.33±9.37	0.000
Smoking history [n (%)]	1748 (24.1%)	1417 (9.6%)	0.000

Notes: Data were expressed as mean ± standard deviation and analyzed by student's *t* test for continuous variables or expressed as number (percentage) and analyzed by chi-square test for categorical variables.

Abbreviations: MAFLD, metabolic dysfunction-associated fatty liver disease; T₂DM, type 2 diabetes mellitus; BMI, body mass index; UA, uric acid; Cr, creatinine; sUA/Cr, serum uric acid to creatinine ratio; FPG, fasting plasma glucose; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; Tbil, total bilirubin; SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumference.




Figure 2 The serum uric acid to creatinine ratio value in metabolic dysfunction-associated fatty liver disease and its subgroups. (A) sUA/Cr values in different subgroups. (B) sUA/Cr values in different sex groups. (C) sUA/Cr values in different age groups (years). Data were expressed as mean \pm standard deviation ($\bar{x} \pm s$) and analyzed by student's *t* test.

Abbreviations: MAFLD, metabolic dysfunction-associated fatty liver disease; sUA/Cr, serum uric acid to creatinine ratio; T₂DM, type 2 diabetes mellitus.

The Correlation Between sUA/Cr and MAFLD in Non-Obese Patients Without T₂DM

The sUA/Cr ratio in non-obese MAFLD patients without T₂DM was higher than that in corresponding controls (5.40 ± 1.17 vs 4.76 ± 1.07 , $P < 0.01$). sUA/Cr was correlated to MAFLD in non-obese individuals without T₂DM (OR=1.587, 95% CI: 1.461–1.723). The correlation was stronger than that in obese patients without T₂DM (OR=1.456, 95% CI: 1.409–1.504), obese patients with T₂DM (OR=1.318, 95% CI: 1.177–1.475), and non-obese patients with T₂DM (OR=1.400, 95% CI: 1.110–1.766) (all $P < 0.01$) (Figure 3). Similar results were observed after adjustment for age, sex, BMI, dyslipidemia, and abnormal liver function (non-obese patients without T₂DM: OR=1.490, 95% CI: 1.359–1.634, $P < 0.01$; obese patients without T₂DM: OR=1.294, 95% CI: 1.247–1.344, $p < 0.01$; obese patients with T₂DM: OR=1.120, $P = 0.074$; non-obese patients with T₂DM: OR=1.380, $P = 0.013$) (Figure 4).

Multivariate Correlation Analysis Stratified by Sex and Age

After correcting for confounders (age, BMI, dyslipidemia, and abnormal liver function), sUA/Cr was correlated to MAFLD in non-obese patients without T₂DM (adjusted OR=1.428, 95% CI: 1.231–1.657, $P < 0.01$) and obese patients without T₂DM (adjusted OR=1.243, 95% CI: 1.188–1.302, $P < 0.01$) in males. No correlation was observed between sUA/Cr and MAFLD in obese patients with T₂DM (OR=1.102, $P = 0.182$) or non-obese patients with T₂DM (OR=1.257, $p = 0.167$). Similar results were obtained in females (non-obese patients without T₂DM: adjusted OR=1.498, 95% CI: 1.332–1.686, $P < 0.01$; obese patients without T₂DM: adjusted OR=1.417, 95% CI: 1.327–1.514, $P < 0.01$; obese patients with T₂DM; adjusted OR=1.157, $P = 0.277$; non-obese patients with T₂DM: adjusted OR=1.525, $P = 0.046$) (Figures 3 and 4).




Figure 3 The univariate correlation analysis between serum uric acid to creatinine ratio and metabolic dysfunction-associated fatty liver diseases. **(A)** Univariate ORs of sUA/Cr in MAFLD and its subgroups. **(B)** Univariate ORs of sUA/Cr in MAFLD and its subgroups in males. **(C)** Univariate ORs of sUA/Cr in MAFLD and its subgroups in females. **(D)** Univariate ORs of sUA/Cr in MAFLD and its subgroups aged 18–39 years old. **(E)** Univariate ORs of sUA/Cr in MAFLD and its subgroups aged 40–59 years old. **(F)** Univariate ORs of sUA/Cr in MAFLD and its subgroups aged ≥ 60 years old.

Abbreviations: MAFLD, metabolic dysfunction-associated fatty liver disease; sUA/Cr, serum uric acid to creatinine ratio; T₂DM, type 2 diabetes mellitus; OR, odds ratio; CI, confidence interval.

The positive association of sUA/Cr with MAFLD in non-obese patients without T₂DM was observed at all age stages (18–39 years old: OR=1.420, 95% CI: 1.231–1.639; 40–59 years old: OR=1.777, 95% CI: 1.575–2.006; ≥ 60 years old: OR=1.665, 95% CI: 1.318–2.105, all $P < 0.01$). Similar results were obtained after correcting for sex, BMI, dyslipidemia, and abnormal liver function (18–39 years old: OR=1.253, 95% CI: 1.072–1.464; 40–59 years old: OR=1.647, 95% CI: 1.443–1.880; ≥ 60 years old: OR=1.610, 95% CI: 1.249–2.075, all $P < 0.01$) (Figures 3 and 4).

The Predictive Value of sUA/Cr for MAFLD in Non-Obese Patients Without T₂DM

It was found that sUA/Cr had a better predictive value for MAFLD in non-obese patients without T₂DM (AUC: 0.667, sensitivity: 58.27%, specificity: 67.42%) than obese patients without T₂DM (AUC: 0.626, sensitivity: 55.24%, specificity:




Figure 4 The multivariate correlation analysis between serum uric acid to creatinine ratio and metabolic dysfunction-associated fatty liver diseases. **(A)** Multivariate ORs of sUA/Cr in MAFLD and its subgroups. **(B)** Multivariate ORs of sUA/Cr in MAFLD and its subgroups in males. **(C)** Multivariate ORs of sUA/Cr in MAFLD and its subgroups in females. **(D)** Multivariate ORs of sUA/Cr in MAFLD and its subgroups aged 18–39 years. **(E)** Multivariate ORs of sUA/Cr in MAFLD and its subgroups aged 40–59 years. **(F)** Multivariate ORs of sUA/Cr in MAFLD and its subgroups aged ≥60 years.

Abbreviations: MAFLD, metabolic dysfunction-associated fatty liver disease; sUA/Cr, serum uric acid to creatinine ratio; T₂DM, type 2 diabetes mellitus; OR, odds ratio; CI, confidence interval.

63.16%) based on ROC analysis ($P < 0.01$), but not non-obese patients with T₂DM (AUC: 0.633, sensitivity: 77.61%, specificity: 47.57%, $P > 0.01$) or obese patients with T₂DM (AUC: 0.620, sensitivity: 72.91%, specificity: 48.60%, $P > 0.01$).

With stratification for sex, both in males and females, sUA/Cr had the ability to predict MAFLD in non-obese patients without T₂DM (AUCs: male: 0.671, sensitivity: 81.29%, specificity: 48.17%; female: 0.665, sensitivity: 50.00%, specificity: 75.81%) and obese patients without T₂DM (AUCs: male: 0.621, sensitivity: 53.21%, specificity: 64.44%; female: 0.659, sensitivity: 67.43%, specificity: 56.59%) (all $P < 0.01$). No statistically significant difference in AUCs was observed between the two groups either in males or in females (all $P > 0.01$).

Stratified by age, sUA/Cr could discriminate for MAFLD at all age stages in non-obese patients without T₂DM (all $P < 0.01$). Moreover, the ability of sUA/Cr to discriminate for MAFLD increased with aging (AUCs: 18–39 years old:

0.637, sensitivity: 65.62%, specificity: 59.19%; 40–59 years old: 0.698, sensitivity: 79.59%, specificity: 51.03%; ≥60 years old: 0.704, sensitivity: 57.78%, specificity: 75.17%; all $P < 0.01$) (Table 2 and Figure 5).

Discussion

MAFLD is the hepatic manifestation of metabolic dysfunction, and the association with UA abnormalities has been studied but the results were controversial. The study conducted by Xing Y et al showed an association between sUA/Cr and MAFLD in patients with type 2 diabetes, which was in accordance with the univariate analysis results in this study.¹⁷ However, the difference between the two studies in that the association was not observed in this study after adjusting for age, BMI, dyslipidemia, and abnormal liver function. Therefore, the difference in confounders adjusted might contribute to the distinguished results. In addition, the larger sample size of this study may lead to a more representative result. Moreover, this study set a more stringent threshold for statistical significance at $p < 0.01$ rather than $p < 0.05$ in Xing Y's study.

Table 2 Receiver Operating Characteristics Analysis of Serum Uric Acid to Creatinine Ratio in Predicting the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease in Different Groups

	Variables	AUC	95% CI	p value	Cutoff Points	Youden Index	Sensibility (%)	Specificity (%)
MAFLD	Overall	0.660	(0.654,0.666)	<0.0001	5.038	0.2400	62.56	61.44
	Male	0.639	(0.630,0.647)	<0.0001	5.035	0.2085	60.24	60.61
	Female	0.714	(0.705,0.723)	<0.0001	5.223	0.3230	64.27	68.03
	Age 18–39	0.692	(0.684,0.700)	<0.0001	5.096	0.2860	66.73	61.86
	Age 40–59	0.652	(0.642,0.662)	<0.0001	5.038	0.2323	58.69	64.54
	Age ≥60	0.626	(0.601,0.652)	<0.0001	5.212	0.2080	52.53	68.28
Obesity without T ₂ DM	Overall	0.626	(0.617,0.634)	<0.0001	5.249	0.1840	55.24	63.16
	Male	0.621	(0.611,0.632)	<0.0001	5.238	0.1765	53.21	64.44
	Female	0.659	(0.643,0.675)	<0.0001	5.123	0.2403	67.43	56.59
	Age 18–39	0.648	(0.635,0.660)	<0.0001	5.130	0.2170	65.63	56.07
	Age 40–59	0.617	(0.603,0.630)	<0.0001	5.038	0.1793	58.21	59.72
	Age ≥60	0.599	(0.563,0.635)	<0.0001	5.356	0.1841	45.48	72.93
Non-obesity without T ₂ DM	Overall	0.667	(0.657,0.676)	<0.0001	5.102	0.2569	58.27	67.42
	Male	0.671	(0.652,0.690)	<0.0001	4.578	0.2946	81.29	48.17
	Female	0.665	(0.654,0.676)	<0.0001	5.395	0.2581	50.00	75.81
	Age 18–39	0.637	(0.624,0.649)	<0.0001	4.912	0.2482	65.62	59.19
	Age 40–59	0.698	(0.680,0.715)	<0.0001	4.589	0.3062	79.59	51.03
	Age ≥60	0.704	(0.652,0.752)	<0.0001	5.298	0.3295	57.78	75.17
Obesity with T ₂ DM	Overall	0.620	(0.591,0.648)	<0.0001	4.719	0.2151	72.91	48.60
	Male	0.612	(0.580,0.644)	<0.0001	4.719	0.2036	70.08	50.28
	Female	0.603	(0.537,0.666)	0.0755	4.885	0.2858	80.10	48.48
	Age 18–39	0.588	(0.502,0.671)	0.2802	5.409	0.2097	70.97	50.00
	Age 40–59	0.612	(0.575,0.648)	0.0001	4.971	0.1957	63.37	56.20
	Age ≥60	0.615	(0.557,0.672)	0.0018	5.341	0.2461	51.89	72.73
Non-obesity with T ₂ DM	Overall	0.633	(0.556,0.706)	0.0019	4.632	0.2518	77.61	47.57
	Male	0.590	(0.485,0.689)	0.1323	4.926	0.2167	58.33	63.33
	Female	0.675	(0.556,0.780)	0.0049	4.632	0.3773	93.55	44.19
	Age 18–39	0.583	(0.317,0.818)	0.5779	5.482	0.4000	100.00	40.00
	Age 40–59	0.718	(0.611,0.809)	0.0001	4.926	0.3851	70.59	67.92
	Age ≥60	0.547	(0.421,0.669)	0.5090	4.645	0.1898	81.48	37.50

Abbreviations: MAFLD, metabolic dysfunction-associated fatty liver disease; T₂DM, type 2 diabetes mellitus; AUC, area under curve; CI, confidence interval.




Figure 5 Receiver operating characteristics analysis of serum uric acid to creatinine ratio in predicting the risk of MAFLD in different groups. **(A)** ROC of overall MAFLD. **(B)** ROC of obesity without T₂DM. **(C)** ROC of non-obesity without T₂DM. **(D)** ROC of obesity with T₂DM. **(E)** ROC of non-obesity with T₂DM.

Abbreviations: ROC, receiver operating characteristics; MAFLD, metabolic dysfunction-associated fatty liver disease; T₂DM, type 2 diabetes mellitus.

UA is the final metabolic product of purine and is excreted by the kidney (~70%) and intestine (~30%).¹⁸ Previous studies showed that UA played a key role in lipid metabolism¹⁹ and was associated with a variety of metabolism-related diseases, such as metabolic syndrome,²⁰ diabetes,²¹ and NAFLD.²² The level of serum Cr is commonly used to measure renal clearance function, which can be affected by the number of muscles and meat intake.²³ Serum UA/Cr is a composite index of renal function-normalized sUA, reflecting endogenous UA levels more precisely than sUA.²⁴

Consistent with this study, Seo YB et al found that the level of sUA/Cr was correlated with NAFLD.²⁵ IR and compensatory hyperinsulinemia progressing to defective lipid metabolism and hepatic triglyceride accumulation are commonly considered as the core pathogenesis mechanism for MAFLD.²⁶ Furthermore, elevated sUA might lead to IR via reducing endothelial nitric oxide (NO) bioavailability,²⁷ downregulating the production of insulin sensitizers, and activating the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome [21,22].

As reported, 60%~70% of NAFLD patients are complicated with T₂DM.²⁸ However, this study revealed that the association of sUA/Cr with MAFLD was observed in patients without T₂DM, but not those with T₂DM, which suggested that in addition to IR and β -cell dysfunction, abnormal UA metabolism may play a critical role in the pathogenesis of MAFLD. Liu N et al indicated that UA could react with some special free radicals and produce stronger free radicals, which induce severe endoplasmic reticulum stress and mitochondrial oxidative stress and interfere with tricarboxylic acid cycle, contributing to the increase in fat synthesis, the impairment of fatty acid oxidation, and development of hepatic steatosis.²⁹

This study also found that in patients without T₂DM, the association of sUA/Cr with MAFLD was stronger in non-obese individuals than in obese individuals. This study doubts that the well-acknowledged association of obesity with MAFLD may mask the effect of UA on MAFLD. In non-obese individuals, the effect of sUA on MAFLD might be more obvious. Moreover, Eun Kyung Choe et al suggested that the prevalence of NAFLD was significantly higher in sarcopenic subjects than in nonsarcopenic subjects, regardless of obesity.³⁰ A higher level of sUA led to sarcopenia and patients with low muscle mass and muscle strength were at a higher risk of NAFLD.^{31–33} IR is a common pathophysiology of sarcopenia and NAFLD because both liver and muscle are target organs for insulin.^{34,35} The loss of muscle mass leads to glucose intolerance and promotes gluconeogenesis by reducing the quantity of the main cellular target for insulin. When IR occurs in myocytes, muscle mass is depleted by the reduction in protein synthesis and the increase in catabolism.^{36,37} Finally, IR and sarcopenia become a vicious cycle. Furthermore, further studies found that non-obese MAFLD patients had a distinct metabolic profile with an increased rate of PNPLA3 risk allele carriage, which may involve specific metabolic pathways and need further exploration.^{38,39}

Strengths

There are some strengths in this study. First, this study is aimed at the association of sUA/Cr with MAFLD in non-obese and obese individuals with or without T₂DM, and the results have certain practical application value. The findings highlight the significance of focusing on the level of sUA/Cr, even though UA is excluded from the diagnostic standards of MAFLD. Furthermore, this study provides new insights into understanding the pathogenesis of MAFLD in addition to IR and obesity, especially for non-obese individuals without T₂DM. The study had a large sample size of 21,996 subjects, and the results obtained are relatively representative.

Limitations

This study does possess some limitations. Firstly, the severity of MAFLD was not classified due to the limitation of ultrasound and the different emphasis in this study. Besides, considering the large sample size of this retrospective study, we did not administer questionnaires regarding physical activity and diet, or measure muscle mass to identify sarcopenia, which may be associated with fatty liver and HUA.^{40,41} In our future cohort studies, we will document physical activity and diet habit, and measure body muscle mass to further explore the risk factors of MAFLD. Finally, this study was a single-center study at a risk of selection bias, but the large sample size compensated for this to some extent.

Conclusions

This large-scale cross-sectional study demonstrated the association of sUA/Cr with non-obese MAFLD in patients without T₂DM. Besides, sUA/Cr was capable of discriminating for MAFLD in non-obese individuals without T₂DM, especially for those over 60 years old. These findings contribute to understanding the effect of sUA on MAFLD and suggest that non-obese individuals without T₂DM should pay more attention to sUA/Cr to prevent MAFLD.

Abbreviations

MAFLD, metabolic dysfunction-associated fatty liver disease; T₂DM, type 2 diabetes mellitus; sUA/Cr, serum uric acid to creatinine ratio; NAFLD, non-alcoholic fatty liver disease; IR, insulin resistance; BMI, body mass index; UA, uric acid; WC, waist circumference; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, gamma-glutamyl transferase; LDL-C, low-density lipoprotein

cholesterol; TC, total cholesterol; TG, triglyceride; TBil, total bilirubin; FPG, fasting plasma glucose; OR, odds ratio; CI, confidence intervals; AUC, area under the curve; ROC, receiver operating characteristic; NLRP3, NOD-like receptor family pyrin domain containing 3.

Data Sharing Statement

All data relevant to the study are included in the article. Data can be provided upon request to credible investigators on verification for patient confidentiality.

Ethics Approval and Consent to Participate

This retrospective study was approved by the ethical review board of the China–Japan Friendship Hospital, No. 2, East Yinghua Road, Chaoyang District, Beijing, 100029, China (Number of Ethics documents: 2018-110-K79-1). The requirement for informed consent was waived owing to the retrospective study design. The data are anonymous.

Acknowledgments

The authors thank the China–Japan Friendship Hospital for support.

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Disclosure

The authors have no relevant financial or non-financial interests to disclose.

References

1. Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. *Clin Sci*. 2022;136(18):1347–1366. doi:10.1042/cs20220572
2. Lim GEH, Tang A, Ng CH, et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. *Clin Gastroenterol Hepatol*. 2021. doi:10.1016/j.cgh.2021.11.038
3. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. *J Hepatol*. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
4. Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? *Gut*. 2022;71(2):382–390. doi:10.1136/gutjnl-2020-322564
5. Ding C, Chan Z, Magkos F. Lean, but not healthy: the ‘metabolically obese, normal-weight’ phenotype. *Curr Opin Clin Nutr Metab Care*. 2016;19(6):408–417. doi:10.1097/mco.0000000000000317
6. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64(1):73–84. doi:10.1002/hep.28431
7. Cruz ACD, Bugianesi E, George J, et al. 379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease. *Int J Med*. 2014;146.
8. Hagström H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. *Hepatol Commun*. 2018;2(1):48–57. doi:10.1002/hep4.1124
9. Kanbay M, Jensen T, Solak Y, et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. *Eur J Internal Med*. 2016;29:3–8. doi:10.1016/j.ejim.2015.11.026
10. Gao X, Fan JG. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. *J Diabetes*. 2013;5(4):406–415. doi:10.1111/1753-0407.12056
11. She D, Xu W, Liu J, et al. Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Patients with Overweight/Obesity. *Diabetes Metabolic Syndrome Obesity*. 2023;16:3007–3017. doi:10.2147/dms0.S427070
12. Tarantino G, Sinatti G, Citro V, Santini SJ, Balsano C. Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression? *Int Emerg Med*. 2023;18(7):1887–1895. doi:10.1007/s11739-023-03339-z
13. Liu X, Chen X, Hu F, et al. Higher uric acid serum levels are associated with sarcopenia in west China: a cross-sectional study. *BMC Geriatr*. 2022;22(1):121. doi:10.1186/s12877-022-02817-x
14. Gu Z, Li D, He H, et al. Body mass index, waist circumference, and waist-to-height ratio for prediction of multiple metabolic risk factors in Chinese elderly population. *Sci Rep*. 2018;8(1):385. doi:10.1038/s41598-017-18854-1
15. Association AD. 2. Classification and Diagnosis of Diabetes. *Diabetes Care*. 2017;40(Suppl 1):S11–s24. doi:10.2337/dc17-S005
16. Rader DJ, Hoeg JM, Brewer HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. *Ann Internal Med*. 1994;120(12):1012–1025. doi:10.7326/0003-4819-120-12-199406150-00008
17. Xing Y, Chen J, Liu J, Song G, Ma H. Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. *Diabetes Metabolic Syndrome Obesity*. 2022;15:257–267. doi:10.2147/dms0.S350468
18. Ndrepepa G. Uric acid and cardiovascular disease. *Int J Clin Chem*. 2018;484:150–163. doi:10.1016/j.cca.2018.05.046

19. Lima WG, Martins-Santos ME, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism. *Biochimie*. 2015;116:17–23. doi:10.1016/j.biochi.2015.06.025
20. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med*. 2007;120(5):442–447. doi:10.1016/j.amjmed.2006.06.040
21. Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. *Am J Epidemiol*. 2012;176(2):108–116. doi:10.1093/aje/kws002
22. Darmawan G, Hamijoyo L, Hasan I. Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: a Meta-Analysis. *Acta medica Indonesiana*. 2017;49(2):136–147.
23. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. *Clin. Chem*. 1992;38(10):1933–1953.
24. Silva NR, Gonçalves CET, Gonçalves DLN, Cotta RMM, da Silva LS. Association of uric acid and uric acid to creatinine ratio with chronic kidney disease in hypertensive patients. *BMC Nephrol*. 2021;22(1):311. doi:10.1186/s12882-021-02521-9
25. Seo YB, Han AL. Association of the Serum Uric Acid-to-Creatinine Ratio with Nonalcoholic Fatty Liver Disease Diagnosed by Computed Tomography. *Metabolic syndrome and related disorders*. Mar. 2021;19(2):70–75. doi:10.1089/met.2020.0086
26. Forlani G, Giorda C, Manti R, et al. The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. *J Diabetes Res*. 2016;2016:2931985. doi:10.1155/2016/2931985
27. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opinion Rheumatol*. 2013;25(2):210–216. doi:10.1097/BOR.0b013e32835d951e
28. Dai W, Ye L, Liu A, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. *Medicine*. 2017;96(39):e8179. doi:10.1097/md.00000000000008179
29. Liu N, Xu H, Sun Q, et al. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors. *Oxid Med Cell Longev*. 2021;2021:1470380. doi:10.1155/2021/1470380
30. Choe EK, Kang HY, Park B, Yang JI, Kim JS. The Association between Nonalcoholic Fatty Liver Disease and CT-Measured Skeletal Muscle Mass. *J Clin Med*. 2018;7(10). doi:10.3390/jcm7100310
31. Gan D, Wang L, Jia M, et al. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease. *Clin Nutr*. 2020;39(4):1124–1130. doi:10.1016/j.clnu.2019.04.023
32. Beavers KM, Beavers DP, Serra MC, Bowden RG, Wilson RL. Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels: findings from NHANES III. *J Nutr Health Aging*. 2009;13(3):177–182. doi:10.1007/s12603-009-0054-5
33. Wijarnpreecha K, Panjawatanan P, Thongprayoon C, Jaruvongvanich V, Ungprasert P. Sarcopenia and risk of nonalcoholic fatty liver disease: a meta-analysis. *Saudi j Gastroenterol*. 2018;24(1):12–17. doi:10.4103/sjg.SJG_237_17
34. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. *J Clin Endocrinol Metab*. 2006;91(12):4753–4761. doi:10.1210/jc.2006-0587
35. Rasmussen BB, Fujita S, Wolfe RR, et al. Insulin resistance of muscle protein metabolism in aging. *FASEB j*. 2006;20(6):768–769. doi:10.1096/fj.05-4607fje
36. Fujita S, Glynn EL, Timmerman KL, Rasmussen BB, Volpi E. Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism. *Diabetologia*. 2009;52(9):1889–1898. doi:10.1007/s00125-009-1430-8
37. Zhai Y, Xiao Q. The Common Mechanisms of Sarcopenia and NAFLD. *Biomed Res Int*. 2017;2017:6297651. doi:10.1155/2017/6297651
38. Feldman A, Eder SK, Felder TK, et al. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. *Am J Gastroenterol*. 2017;112(1):102–110. doi:10.1038/ajg.2016.318
39. Argo CK, Henry ZH. Editorial: “Lean” NAFLD: metabolic Obesity with Normal BMI... Is It in the Genes? *Am J Gastroenterol*. 2017;112(1):111–113. doi:10.1038/ajg.2016.527
40. Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. *Clin j Am Society Nephrology*. 2008;3(2):348–354. doi:10.2215/cjn.02870707
41. Li R, Yu K, Li C. Dietary factors and risk of gout and hyperuricemia: a meta-analysis and systematic review. *Asia Pacific J Clin Nutrition*. 2018;27(6):1344–1356. doi:10.6133/apjcn.201811_27(6).0022

Diabetes, Metabolic Syndrome and Obesity

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>